5e5 of anti-CLEC12A/CLL-1 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CLEC12A, His Tag (Cat. No. CLA-HP2Q3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Immobilized Biotinylated Human CLEC12A, His,Avitag (Cat. No. CLA-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Monoclonal Anti-Human CLEC12A Antibody, Human IgG1 with a linear range of 0.1-0.8 ng/mL (QC tested).
The purity of Human CLEC12A, Fc Tag (Cat. No. CLA-H5266) is more than 90% and the molecular weight of this protein is around 125-140 kDa verified by SEC-MALS.
Immobilized Human CLEC12A, Fc Tag (Cat. No. CLA-H5266) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CLEC12A Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| CLL1-CD33 cCART cell therapy (iCell Gene Therapeutics) | CLL1-CD33-cCAR | Phase 1 Clinical | Icell Gene Therapeutics, Chengdu Military General Hospital | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hematologic Neoplasms; Myeloproliferative Disorders; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| KITE-222 | Phase 1 Clinical | Kite Pharma | Leukemia, Myeloid, Acute | Details | |
| ICG-136 | ICG-136 | Phase 1 Clinical | Icell Gene Therapeutics | Leukemia, Myeloid, Acute | Details |
| Anti-CLL1 CAR T cell therapy (The First Affiliated Hospital of Soochow University) | Phase 2 Clinical | Leukemia, Myeloid, Acute | Details | ||
| CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University) | Phase 3 Clinical | Fujian Medical University | Leukemia, Myeloid, Acute | Details | |
| Anti-CD33/CLL-1 CAR-T (Legend) | Phase 1 Clinical | Leukemia, Promyelocytic, Acute | Details | ||
| CLL-1.CAR T cell therapy (Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Leukemia, Myeloid, Acute | Details | |
| Tepoditamab | MCLA-117 | Phase 1 Clinical | Pharmaceutical Research Associates, Merus, Vu University Medical Center, Lgc, Institute Gustave-Roussy | Leukemia, Myeloid, Acute | Details |
| Anti-CD33/CLL1 CAR-NK Cell Therapy | Amador Biomedicine (Hangzhou) Co Ltd | Details |
This web search service is supported by Google Inc.
A-Z
